Johnson & Johnson announced positive topline results from ICONIC-LEADa, a pivotal Phase 3 investigational study of icotrokinra, or JNJ-2113, the first targeted oral peptide that selectively blocks the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback